Atara Biotherapeutics Inc. priced an offering of 4,285,714 shares at $35 each to raise $150 million in gross proceeds.
The South San Francisco, Calif.-based company, which is developing treatments for cancer, expects to close the offering by March 5 with J.P. Morgan and Cowen acting as joint book-running managers.
Canaccord Genuity Inc. and Mizuho Securities USA LLC are acting as co-managers.
The underwriters have an option to buy up to an additional 642,857 shares.
